查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602831

抗真菌藥物市場：按感染類型、劑型和治療適應症分類 - 全球預測 2025-2030

Antifungal Drugs Market by Infection Type (Superficial Fungal Infection, Systemic Fungal infection), Type (Allylamines, Azoles, Echinocandins), Form, Therapeutic Indications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗真菌藥物市值為148.9億美元，預計2024年將達到158億美元，複合年成長率為6.19%，預計到2030年將達到226.9億美元。

抗真菌藥物市場涵蓋了為治療感染人體各部位的真菌感染疾病而開發的廣泛藥物類別。這些感染疾病的範圍從皮膚和指甲等淺層感染疾病到影響內臟器官的系統性、可能危及生命的疾病。對抗真菌藥物的需求主要是由於全球人口成長、都市化以及愛滋病和癌症等免疫力缺乏低下感染疾病的推動，真菌感染發病率不斷上升。抗真菌藥物用途廣泛，從治療足癬的非處方藥到治療侵襲性麴菌症等嚴重感染疾病的處方藥。主要最終用戶包括醫院、診所和家庭護理機構，它們對於這些藥物的分配和管理至關重要。

主要市場統計
基準年[2023] 148.9億美元
預測年份 [2024] 158億美元
預測年份 [2030] 226.9億美元
複合年成長率（%） 6.19%

市場成長受到對真菌感染疾病認知的提高、藥物配方的進步以及研究經費的增加等因素的影響。此外，醫院感染的增加增加了對更有效和快速起效的抗真菌治療的需求。該公司看到了這個市場的潛在機會，包括開拓新的藥物類別、改進的藥物輸送系統以及針對多重抗藥性菌株的標靶治療。製藥業內對研發和策略聯盟的持續投資對於利用這些機會至關重要。

然而，市場成長受到抗藥性、目前治療的副作用以及嚴格的藥物核准監管政策的限制。此外，藥物開發的高成本和開拓市場所需的大量時間是主要挑戰。最佳創新領域包括基因組研究，以了解真菌病原體的抗藥性機制以及尋找天然來源的抗真菌化合物。市場充滿活力且競爭激烈，學名藥製造商的競爭非常激烈，需要具有成本效益的解決方案。投資尖端研究和策略聯盟以提高抗真菌功效並減少副作用的公司將在這個不斷變化的市場環境中處於有利地位。

市場動態：揭示快速發展的抗真菌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗真菌藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球真菌感染疾病流行
    • 對多種真菌感染疾病的高度認知
    • 政府對抗真菌藥物的有利核准
  • 市場限制因素
    • 繼續偏好傳統抗真菌藥物
  • 市場機會
    • 加大研發投入，注重產品創新
    • 抗真菌藥物策略聯盟和夥伴關係
  • 市場挑戰
    • 假藥的存在和品牌藥品專利到期

波特五力：駕馭抗真菌藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗真菌藥物市場的外部影響

外部宏觀環境因素在塑造抗真菌藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗真菌藥物市場的競爭格局

抗真菌藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗真菌藥物市場供應商績效評估

FPNV定位矩陣是評估抗真菌藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪抗真菌藥物市場的成功之路

抗真菌藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球真菌感染疾病率增加
      • 對各種真菌感染疾病的意識層級
      • 政府對抗真菌藥物的有利核准
    • 抑制因素
      • 傳統抗真菌藥物仍然是優先考慮的
    • 機會
      • 加大研發投入，注重產品創新
      • 抗真菌藥物策略聯盟和夥伴關係
    • 任務
      • 假藥的存在和品牌藥品的專利到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

抗真菌藥物市場

  • 表層真菌感染疾病
  • 全身性真菌感染疾病

第7章抗真菌藥物市場：按類型

  • Allylamines
    • 布替萘芬
    • Naftifine
    • Terbinafine
  • Azole
    • 咪唑
    • 噻唑
    • Voricanazole
  • Echinocandins
    • 阿尼杜拉·芬金
    • Caspofungin
    • Micafungin
  • Polyenes
    • 兩性黴素B
    • 念珠菌素
    • 哈黴素
    • 遊黴素

抗真菌藥物市場：按形式

  • 軟膏
  • 粉末
  • 藥片

抗真菌藥物市場

  • 麴菌症
  • 念珠菌症
  • 皮膚絲狀菌症

第10章美洲抗真菌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗真菌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲抗真菌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bayer HealthCare Pharmaceuticals LLC
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cadila Pharmaceuticals Limited
  • Cardinal Health, Inc.
  • Cipla, Inc.
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lakewood-Amedex, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Quest Diagnostics Incorporated
  • SCYNEXIS, Inc.
  • Sigma-Aldrich, Inc.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-4312A385A460

The Antifungal Drugs Market was valued at USD 14.89 billion in 2023, expected to reach USD 15.80 billion in 2024, and is projected to grow at a CAGR of 6.19%, to USD 22.69 billion by 2030.

The antifungal drugs market is dedicated to the broad category of pharmaceuticals developed to treat fungal infections, which affect various parts of the human body. These infections range from superficial, like skin or nail infections, to systemic and potentially life-threatening diseases affecting internal organs. The necessity for antifungal medications is primarily driven by the rising incidence of fungal infections, spurred by increasing global populations, urbanization, and immunocompromised conditions such as AIDS and cancer. Applications of antifungal drugs are extensive, including over-the-counter treatments for athlete's foot to prescription medications for more severe infections like invasive aspergillosis. Key end-users include hospitals, clinics, and home-care settings, which are crucial to distributing and administering these medications.

KEY MARKET STATISTICS
Base Year [2023] USD 14.89 billion
Estimated Year [2024] USD 15.80 billion
Forecast Year [2030] USD 22.69 billion
CAGR (%) 6.19%

Market growth is influenced by factors such as increased awareness about fungal infections, advancements in drug formulations, and a rise in research funding. Additionally, the incidence of hospital-acquired infections is driving demand for more effective and rapid-acting antifungal treatments. The market sees potential opportunities in the development of novel drug classes, improved drug-delivery systems, and targeted therapies for multidrug-resistant strains. To capitalize on these opportunities, continued investment in R&D and strategic partnerships within the pharmaceutical industry are essential.

However, market growth faces limitations, including drug resistance, adverse side effects of current treatments, and stringent regulatory policies for drug approval. Furthermore, the high cost of drug development and the extensive time required for market introduction present significant challenges. Best areas of innovation include genomic research to understand fungal pathogens' resistance mechanisms and the exploration of naturally derived antifungal compounds. The market is dynamic and competitive, with strong competition from generic drug manufacturers pushing for cost-effective solutions. Businesses that invest in cutting-edge research and strategic collaborations to enhance antifungal efficacy and reduce side effects are poised for advantageous positioning in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antifungal Drugs Market

The Antifungal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of fungal infection among population worldwide
    • High awareness levels pertaining to myriad fungal infections
    • Favorable government approvals for antifungal drugs
  • Market Restraints
    • Continued preference for conventional antifungal drugs
  • Market Opportunities
    • Increased R&D funding and focus on product innovation
    • Stategic alliances and partnerships for antifungal drugs
  • Market Challenges
    • Presence of counterfeit drugs and patent expiration of branded drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antifungal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antifungal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antifungal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antifungal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antifungal Drugs Market

A detailed market share analysis in the Antifungal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antifungal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antifungal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antifungal Drugs Market

A strategic analysis of the Antifungal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antifungal Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., Bayer HealthCare Pharmaceuticals LLC, Becton, Dickinson and Company, bioMerieux SA, Cadila Pharmaceuticals Limited, Cardinal Health, Inc., Cipla, Inc., Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Hologic, Inc., Johnson & Johnson, Lakewood-Amedex, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Quest Diagnostics Incorporated, SCYNEXIS, Inc., Sigma-Aldrich, Inc., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antifungal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection Type, market is studied across Superficial Fungal Infection and Systemic Fungal infection.
  • Based on Type, market is studied across Allylamines, Azoles, Echinocandins, and Polyenes. The Allylamines is further studied across Butenafine, Naftifine, and Terbinafine. The Azoles is further studied across Imidazoles, Thiazoles, and Voricanazole. The Echinocandins is further studied across Anidulafungin, Caspofungin, and Micafungin. The Polyenes is further studied across Amphotericin B, Candicidin, Hamycin, and Natamycin.
  • Based on Form, market is studied across Ointments, Powder, and Tablets.
  • Based on Therapeutic Indications, market is studied across Aspergillosis, Candidiasis, and Dermatophytosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of fungal infection among population worldwide
      • 5.1.1.2. High awareness levels pertaining to myriad fungal infections
      • 5.1.1.3. Favorable government approvals for antifungal drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Continued preference for conventional antifungal drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased R&D funding and focus on product innovation
      • 5.1.3.2. Stategic alliances and partnerships for antifungal drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit drugs and patent expiration of branded drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antifungal Drugs Market, by Infection Type

  • 6.1. Introduction
  • 6.2. Superficial Fungal Infection
  • 6.3. Systemic Fungal infection

7. Antifungal Drugs Market, by Type

  • 7.1. Introduction
  • 7.2. Allylamines
    • 7.2.1. Butenafine
    • 7.2.2. Naftifine
    • 7.2.3. Terbinafine
  • 7.3. Azoles
    • 7.3.1. Imidazoles
    • 7.3.2. Thiazoles
    • 7.3.3. Voricanazole
  • 7.4. Echinocandins
    • 7.4.1. Anidulafungin
    • 7.4.2. Caspofungin
    • 7.4.3. Micafungin
  • 7.5. Polyenes
    • 7.5.1. Amphotericin B
    • 7.5.2. Candicidin
    • 7.5.3. Hamycin
    • 7.5.4. Natamycin

8. Antifungal Drugs Market, by Form

  • 8.1. Introduction
  • 8.2. Ointments
  • 8.3. Powder
  • 8.4. Tablets

9. Antifungal Drugs Market, by Therapeutic Indications

  • 9.1. Introduction
  • 9.2. Aspergillosis
  • 9.3. Candidiasis
  • 9.4. Dermatophytosis

10. Americas Antifungal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antifungal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antifungal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. Bayer HealthCare Pharmaceuticals LLC
  • 4. Becton, Dickinson and Company
  • 5. bioMerieux SA
  • 6. Cadila Pharmaceuticals Limited
  • 7. Cardinal Health, Inc.
  • 8. Cipla, Inc.
  • 9. Enzon Pharmaceuticals, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Gilead Sciences, Inc.
  • 12. Hologic, Inc.
  • 13. Johnson & Johnson
  • 14. Lakewood-Amedex, Inc.
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Pfizer, Inc.
  • 18. Quest Diagnostics Incorporated
  • 19. SCYNEXIS, Inc.
  • 20. Sigma-Aldrich, Inc.
  • 21. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIFUNGAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIFUNGAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIFUNGAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIFUNGAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY BUTENAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NAFTIFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY IMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THIAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VORICANAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ANIDULAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDICIDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NATAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MI